Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANISE basket study of trastuzumab deruxtecan in HER2-positive oligometastatic breast cancer
NL-OMON60486Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in breast cancer, sponsored by Netherlands Cancer Institute. Started May 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60486.